Characterization of a Specific Receptor for Somatomedin C (SM-C) on Cultured Human Lymphocytes: Evidence that SM-C Modulates Homologous Receptor Concentration*
- 1 December 1980
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 107 (6), 1841-1848
- https://doi.org/10.1210/endo-107-6-1841
Abstract
A membrane receptor for somatomedin C (SMC) on cultured IM-9 cells has recently been reported. The current studies were undertaken to further characterize this intact cellular receptor in terms of both kinetics and specificity and to investigate the ability of SM-C to induce homologous receptor loss. The binding of [125I]iodo-SM-C was rapid, achieving a steady state within 90 min and was greater than 95% reversible. Specific binding at 15 C averaged 25–30% for 20 × 106 cells/ml. Competition for binding was observed at SM concentrations as low as 2 mU/ml, with half-maximal displacement of [l25I]iodo- SM-C at SM concentrations of 33 mU/ml (3.33 × 10-9 M). Insulin-like growth factor I (IGF-I) and a purified SM-C preparation were approximately equipotent in their ability to displace [l25I]iodo-SM-C from the IM-9 receptor. The relative potencies of other growth-related peptides, in comparison with SM-C/ IGF-I, were IGF-II (1:10), multiplication stimulating activity (1: 10), insulin (1:100), and hGH (nonreactive). Preexposure of IM-9 cells to SM-C at 37 C resulted in a timeand concentration-dependent reduction in [l25I]iodo-SM-C. A 10–15% decrease in binding was observed after preincubation with SM in concentrations of 7 mU/ml. Preincubation with 100 mU/ml SM resulted in 50% reduction in binding, but no further decreases were observed after preincubation with higher concentrations of SM (up to 1 U/ml). Scatchard analysis indicated that the reduction in binding was due to a loss of available specific receptors on the cell membrane. These data indicate that the IM-9 cell possesses a specific SM receptor and that SM-C and IGF-I compete equally for occupancy. Furthermore, the data provide a direct demonstration in cell culture that SM-C, like insulin and growth hormone, can modulate homologous receptor concentrations and potentially alter target-cell sensitivity.Keywords
This publication has 12 references indexed in Scilit:
- Increased Somatomedin Receptor Sites in Newborn Circulating Mononuclear Cells*Journal of Clinical Endocrinology & Metabolism, 1979
- Comparison of [125I]Somatomedin A and [125I]Somatomedin C Radioreceptor Assays for Somatomedin Peptide Content in Whole and Acid-Chromatographed Plasma*Journal of Clinical Endocrinology & Metabolism, 1978
- Insulin‐Like Growth Factors I and II: Some Biological Actions and Receptor Binding Characteristics of Two Purified Constituents of Nonsuppressible Insulin‐Like Activity of Human SerumEuropean Journal of Biochemistry, 1978
- Demonstration of Specific Plasma Protein Binding Sites For SomatomedinJournal of Clinical Endocrinology & Metabolism, 1977
- Estimation of Somatomedin-C Levels in Normals and Patients with Pituitary Disease by RadioimmunoassayJCI Insight, 1977
- Insulin Binding in Diabetes: Relationships with Plasma Insulin Levels and Insulin SensitivityDiabetes, 1977
- Identification of a Receptor for Somatomedin-Like Polypeptides in Human Fibroblasts*Journal of Clinical Endocrinology & Metabolism, 1977
- Specific 125I-somatomedin receptor on circulating human mononuclear cellsBiochemical and Biophysical Research Communications, 1977
- Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II.Proceedings of the National Academy of Sciences, 1976
- Decreased insulin binding to adipocytes and circulating monocytes from obese subjects.JCI Insight, 1976